Michael Culme-Seymour, Marken's Vice President Asia Pacific Region, commented on the goals of both organizations, "This is an exciting partnership and represents a new and superior level of service for our clinical trial and life science clients. Through this partnership, Green Cross can extend its service offering from clients in Korea to the global market via Marken. The partnership offers numerous opportunities including joint sales and operations, the development of RFID technology and depot development."
Bok-Soo Park, Chief Executive Officer of Green Cross LabCell said, "We expect to create better service for the international businesses in the life sciences industry through Marken's global network." He also said "Through this partnership, we plan to continue expanding to global market customers."
Marken's expanding network of Marken offices and depots will enable them to work closely with Green Cross to build on and expand services around RFID and GPS technology to improve the constant monitoring of biological shipments. Both companies are planning areas of cooperation around joint logistics, both in Korea and internationally.
Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to Patient services and biological sample shipments, and offers a state of the art GMP-compliant depot network and logistic hubs in 43 locations worldwide. Marken's 630 staff members manage 50,000 drug and biological shipments every month at all temperature ranges in more than 150 countries. Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken's unique position in the pharma and logistics industry.
About Green Cross LabCell
Green Cross LabCell is a biotechnology company newly established in July 2011 based on Cell Therapy, Cell Banking, Clinical Laboratory Service, Central Lab Business and Bio logistics that Green Cross Corporation strategically focuses its energies on. Especially in the world's first stem cell therapy product was commercialized in Korea in 2011. Green Cross LabCell has selected Natural killer (NK) cell based immune cell therapy that is currently in Phase II clinical trials and stem cell therapy for incurable diseases as the core strategic projects. We will continue to concentrate our effort on these 5 core business areas to become a global leader.
Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/marken-and-green-cross-labcell-sign-mou-300276775.html